Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Granisetron
Drug ID BADD_D01040
Description A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Indications and Usage For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
Marketing Status approved; investigational
ATC Code A04AA02
DrugBank ID DB00889
KEGG ID D04370
MeSH ID D017829
PubChem ID 5284566
TTD Drug ID D0J5KF
NDC Product Code 14778-0202; 47426-101; 63850-7308; 42747-726; 53104-7609; 55111-841; 55718-117; 54871-1091
UNII WZG3J2MCOL
Synonyms Granisetron | 1-Methyl-N-(endo-9-Methyl-9-Azabicyclo(3.3.1)non-3-yl)-1H-Indazole-3-Carboxamide | Kytril | BRL-43694A | BRL 43694A | BRL43694A | BRL-43694 | BRL 43694 | BRL43694 | Granisetron Hydrochloride | Hydrochloride, Granisetron | Granisetron Monohydrochloride | Monohydrochloride, Granisetron
Chemical Information
Molecular Formula C18H24N4O
CAS Registry Number 109889-09-0
SMILES CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tremor17.01.06.002--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular arrhythmia02.03.04.006--
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.062377%
Application site vesicles08.02.01.009; 23.03.01.009; 12.07.01.0090.014045%Not Available
Application site dryness08.02.01.011; 23.03.03.024; 12.07.01.0110.010534%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Application site swelling12.07.01.027; 08.02.01.0270.010534%Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.024579%Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Malnutrition14.03.02.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.0490.007023%Not Available
Inner ear disorder04.04.02.002--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Increased bronchial secretion22.12.01.002--Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.007023%Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.0380.017556%Not Available
Puncture site pain12.07.04.002; 08.02.04.001--Not Available
Liver injury12.01.17.012; 09.01.07.022--Not Available
Injury associated with device12.01.08.035; 08.07.01.0120.010534%Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Application site mass08.02.01.053; 12.07.01.0530.007023%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene